Simona Potenza
Overview
Explore the profile of Simona Potenza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
28
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sportiello L, La Mantia G, Panzarella V, Colella G, Potenza S, Oteri G, et al.
Oral Dis
. 2024 Oct;
PMID: 39370676
Objectives: The aim of this study was to perform a descriptive analysis of oropharyngeal adverse events (AEs) related to drugs and/or vaccines in order to provide useful information for clinicians....
2.
Maggini V, Crescioli G, Ippoliti I, Gallo E, Menniti-Ippolito F, Chiaravalloti A, et al.
J Clin Med
. 2023 Jul;
12(14).
PMID: 37510843
Vitamin D (VitD) is largely used in Italy, often inappropriately; thus, an evaluation of its safety is a crucial issue. This study analyses the adverse reactions (ARs) associated with the...
3.
Lombardi N, Crescioli G, Maggini V, Brilli V, Menniti-Ippolito F, Ippoliti I, et al.
Ann Ist Super Sanita
. 2022 Jun;
58(2):131-138.
PMID: 35722800
Introduction: Products containing anthraquinones (AQ) are associated with an increased risk of serious adverse events (AEs). We performed an update of the available evidence retrieved by the spontaneous reports of...
4.
Dipasquale V, Cicala G, Lagana F, Cutroneo P, Felicetti P, Potenza S, et al.
Expert Opin Drug Saf
. 2021 Sep;
21(1):127-132.
PMID: 34494498
Background: The use of proton pump inhibitors (PPIs) has increased in the last 10 years in children. Data regarding their safety profile are limited. The aim of this study was...
5.
Cutroneo P, Giardina C, Ientile V, Potenza S, Sottosanti L, Ferrajolo C, et al.
Drug Saf
. 2017 Jun;
40(11):1131-1140.
PMID: 28585152
Introduction: Anti-vascular endothelial growth factor (anti-VEGF) drugs are widely used for the treatment of several cancers and retinal diseases. The systemic use of anti-VEGF drugs has been associated with an...
6.
Magro L, Arzenton E, Moretti U, Sottosanti L, Potenza S, Leone R
Expert Opin Drug Saf
. 2016 Nov;
15(sup2):69-75.
PMID: 27875920
Objectives: Our aim was to investigate the ADR reports of drugs with a monitoring registry (MR drugs), in particular those related to abuse/misuse, medication error, overdose, which might indicate an...
7.
Parretta E, Sottosanti L, Sportiello L, Rafaniello C, Potenza S, DAmato S, et al.
Expert Opin Drug Saf
. 2014 Aug;
13 Suppl 1:S31-40.
PMID: 25171157
Objective: Although bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ) is well recognized, little is known about it in terms of pathophysiology, epidemiology or management. We analyzed all suspected BRONJ reports...
8.
Rafaniello C, Lombardo F, Ferrajolo C, Sportiello L, Parretta E, Formica R, et al.
Eur J Clin Pharmacol
. 2013 Oct;
70(2):187-95.
PMID: 24145814
Purpose: To evaluate the effect of a broad range of covariates on the survival of a real-life long-term follow-up cohort of community-dwelling patients with behavioural and psychological symptoms of dementia...
9.
Potenza S, Nasti G, Ottaiano A, Alessandro O, Filippelli A, Rossi F, et al.
Invest New Drugs
. 2009 Apr;
28(2):185-6.
PMID: 19352593
A 46-year-old man with adenocarcinoma of the sigmoid colon developed a hypersensitivity reaction after the sixth cycle of combination chemotherapy with oxaliplatin infusion. Hypersensitivity to oxaliplatin occurring, after several courses...